PLUS THERAPEUTICS, Inc. (PSTV) Fair Value 2026

PSTV · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 10 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-07-15, PLUS THERAPEUTICS, Inc. (PSTV) trades at $4.08, approximately 336% above CirclFi’s Bayesian DCF fair value of $0.94. QOC: 4.7/10. Value Trap Risk: 36/100 (LOW). 10/13 models active.

Key Facts

Ticker
PSTV
Price
$4.08
Quality Score
4.7/10
Value Trap Risk
36/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

Is PLUS THERAPEUTICS, Inc. (PSTV) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, PLUS THERAPEUTICS, Inc. (PSTV) appears overvalued as of : the median of 10 independent fair value estimates is $0.98, 76.0% below the current price of $4.08. Estimates range from $0.07 to $4.25. PSTV scores 4.7/10 on fundamental quality and 36/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy PLUS THERAPEUTICS, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($4.08)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.94 -77.1%
CUCE Ensemble
Low Conviction
 $1.28 -68.7%
First Chicago
Low Conviction
 $0.10 -97.5%
Dynamic NAV
Medium Conviction
 $0.34 -91.6%

Unlock the Full Matrix

Access 6 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is PLUS THERAPEUTICS, Inc. (PSTV) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, PLUS THERAPEUTICS, Inc.'s intrinsic value is estimated at $1.29, suggesting the stock is overvalued at its current price of $4.08. With 9 out of 10 models flagging downside (-68.3% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $4.25 (+4.2%), while ML-RIV — the most conservative — estimates $0.07 (-98.4%). This +102.6% gap reflects genuine analytical uncertainty about PLUS THERAPEUTICS, Inc.'s intrinsic worth.

What Do the Models Say About PSTV?

10 of 13 models are currently active for PSTV. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates PSTV's intrinsic value at $0.94, implying -77.1% downside from the current price. See which stocks rank higher →

How Does PSTV Rank in Surgical & Medical Instruments & Apparatus?

Among 109 Surgical & Medical Instruments & Apparatus stocks, PSTV ranks #94 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

PLUS THERAPEUTICS, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is PSTV a Value Trap?

CirclFi's Value Trap algorithm assigns PSTV a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for PLUS THERAPEUTICS, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, PLUS THERAPEUTICS, Inc. is rated at 4.7/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +102.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PSTV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PSTV's 10 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy PLUS THERAPEUTICS, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

DXCMDexCom, Inc.QOC 10.0IRMDiRadimed CorporationQOC 10.0PODDInsulet CorporationQOC 10.0RMDResMed Inc.QOC 10.0WSTWest Pharmaceutical Services, IQOC 9.9HAEHaemonetics CorporationQOC 9.8LMATLeMaitre Vascular, Inc.QOC 9.8GMEDGlobus Medical, Inc.QOC 9.2

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About PLUS THERAPEUTICS, Inc.

What is PLUS THERAPEUTICS, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, PLUS THERAPEUTICS, Inc. (PSTV) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.94. The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PSTV overvalued or undervalued right now?

At $4.08, 1 of 10 active models suggest PSTV may be undervalued, while 9 indicate potential overvaluation. The median of all 10 fair value estimates is $0.98, 76.0% below the current price of $4.08 — a consensus view that PSTV is overvalued. The assessment depends on which methodology best fits PLUS THERAPEUTICS, Inc.'s business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 4.7 mean for PSTV?

PLUS THERAPEUTICS, Inc.'s QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PSTV?

CirclFi analyzes PSTV with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is PSTV a value trap in 2026?

PLUS THERAPEUTICS, Inc.'s Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, PLUS THERAPEUTICS, Inc. (PSTV) has a median fair value of $0.98 — 76.0% below the current price of $4.08 — as of 2026-07-15.” Source: circlfi.com/stock/PSTV/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on PSTV.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access